CAMP4 Therapeutics (CAMP.US) Announces IPO Plans, Targeting a Valuation of $283M
AInvestMonday, Oct 7, 2024 8:10 am ET
1min read
CMP --
KALU --

Biopharmaceutical company CAMP4Therapeutics (CAMP.US), supported by healthcare giant Kaiser Permanente, said Monday it will seek a target valuation of up to $283 million in its U.S. initial public offering. CAMP4 plans to issue 5 million shares at a price of between $14 and $16 each, raising up to $80 million.

As the long-awaited policy easing cycle begins, the company will join a recent wave of biotech IPOs. Start-ups are also seeking to get in before the uncertainty that may come with the upcoming U.S. presidential election.

The Cambridge, Massachusetts-based company is developing therapies for a range of genetic diseases. Its lead candidate, CMP-CPS-001, is being evaluated in early clinical trials for the most common urea cycle disorder.

CAMP4 is led by Josh Mandelbrehm, who worked at Biogen (BIIB.US) and Sanofi (SNY.US). The company will list on the Nasdaq under the ticker "CAMP." Morgan Stanley, Leerink Partners, Piper Sandler and William Blair are underwriters for the IPO.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.